Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Drug-induced immune-complex disease.

E Sim1

  • 1Department of Pharmacology, University of Oxford, UK.

Complement and Inflammation
|January 1, 1989
PubMed
Summary
This summary is machine-generated.

Certain drugs like hydralazine and isoniazid can cause drug-induced lupus by interfering with complement C4 binding. This interaction, particularly with C4A, may lead to immune complex deposition and toxic side effects in susceptible individuals.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

'Who Listens to the Listener, Who Cares for the Carer?' A Cross-Sectional Study of Social Connectedness and Sleep Experiences of Young Siblings of Neurodivergent People.

Child: care, health and development·2024
Same author

Human VEGF165-myoblasts produce concomitant angiogenesis/myogenesis in the regenerative heart.

Molecular and cellular biochemistry·2016
Same author

Multivariate assessment of site of lingual nerve.

The British journal of oral & maxillofacial surgery·2015
Same author

Arylamine N-acetyltransferases: from drug metabolism and pharmacogenetics to drug discovery.

British journal of pharmacology·2014
Same author

Management of femoral fractures with an interlocking nail system in patients with age-related complicating factors Experience of 25 cases.

European journal of orthopaedic surgery & traumatology : orthopedie traumatologie·2013
Same author

Arylarnine N-acetyltransferase as a potential biornarker in bladder cancer: fluorescent in situ hybridization and irnmunohistochernistry studies.

Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals·2013
Same journal

Computer-assisted kinetic assay for quantification of total complement activity.

Complement and inflammation·1991
Same journal

HLA complement markers in Italian narcoleptic patients with special emphasis on BfF subtyping.

Complement and inflammation·1991
Same journal

Sarcoidosis and major histocompatibility complex genes with special emphasis on BF F subtypes.

Complement and inflammation·1991
Same journal

Clinical manifestations in humans of combined C7 and C4 deficiency associated with low levels of C2, C8, and C9.

Complement and inflammation·1991
Same journal

Biomedical polymers differ in their capacity to activate complement.

Complement and inflammation·1991
Same journal

Bibliography of complement research for 1989.

Complement and inflammation·1991
See all related articles

Area of Science:

  • Immunology
  • Pharmacology
  • Genetics

Background:

  • Drug-induced lupus erythematosus (DILE) shares similarities with idiopathic SLE.
  • Complement deficiencies (C1, C4, C2) are linked to idiopathic SLE, impacting immune complex clearance.
  • Protein antigens in immune complexes preferentially interact with the C4A isotype.

Purpose of the Study:

  • To investigate the mechanism by which hydralazine, isoniazid, procainamide, and penicillamine induce SLE-like toxic side effects.
  • To determine the role of complement component C4, specifically its isotypes C4A and C4B, in drug-induced immunotoxicity.
  • To explore the metabolic pathways of these drugs and their association with genetic polymorphisms in N-acetyltransferase.

Main Methods:

  • Assessing the effect of hydralazine, isoniazid, and penicillamine on the covalent binding of C4 to activated surfaces.

Related Experiment Videos

  • Investigating the interaction of these drugs and procainamide metabolites with C4 isotypes (C4A and C4B).
  • Correlating drug metabolism via N-acetyltransferase (NAT) polymorphism with the risk of drug-induced lupus.

    • Main Results:

    • Hydralazine, isoniazid, and penicillamine inhibit C4 covalent binding, with greater inhibition of C4A than C4B.
    • These drugs form covalent bonds with C4, potentially contributing to immune complex deposition.
    • Procainamide's hydroxylamine metabolite, not the parent drug, inhibits C4 binding, particularly in slow acetylators.
    • Slow acetylators of N-acetyltransferase are at higher risk for drug-induced lupus.

    Conclusions:

    • Inhibition of C4 binding, especially C4A, by drugs and their metabolites is a key factor in drug-induced lupus.
    • Metabolic pathways and genetic variations (e.g., NAT polymorphism) influence susceptibility to drug-induced immunotoxicity.
    • Assessing C4 type in patients may help identify individuals at risk for drug-induced immune complex disorders.